navigating the updated anaphylaxis parameters导航更新后的过敏反应参数.pdfVIP

ORIGINAL ARTICLE Navigating the Updated Anaphylaxis Parameters Stephen F. Kemp, MD Anaphylaxis, an acute and potentially lethal multi-system clinical syndrome resulting from the sudden, systemic degranulation of mast cells and basophils, occurs in a variety of clinical scenarios and is almost unavoidable in medical practice. Healthcare professionals must be able to recognize its features, treat an episode promptly and appropriately, and be able to provide recommendations to prevent future episodes. Epinephrine, administered immediately, is the drug of choice for acute anaphylaxis. The discussion provides an overview of one set of evidence-based and consensus parameters for the diagnosis and management of anaphylaxis. Key words: anaphylaxis, epinephrine, management, prevention ith the clear objective of improving the quality of In keeping with this spirit, the following discussion Wpatient care through the provision of evidence- focuses on material deemed to be substantively updated or based and consensus guidelines for anaphylaxis, ‘‘The changed from the 1998 parameters. Any discussion that Diagnosis and Management of Anaphylaxis: An Updated may depart from consensus or reflect personal opinion is Practice Parameter’’ was developed by the Joint Task Force clearly designated. on Practice Parameters,1 which represents the American Academy of Allergy, Asthma and Immunology (AAAAI); Background the American College of Allergy, Asthma and Immunology Anaphylaxis is not a reportable disease, and both its (ACAAI); and the Joint Council of Allergy, Asthma and